Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Market Wrap: Initial Claims Show Modest Gain; GE Bring on Q1 Beat; Wal-mart Gets into Money-Transfer Game
- Streetinsider.com After-Hours Movers 04/17: (AMD) (SCSS) Higher; (ACTG) (AVGO) (ATHN) Lower
- Advanced Micro Devices, Inc. (AMD) Tops Q1 EPS by 2c; Sees Q2 Revs +/- 3% Q/Q
- General Electric (GE) Tops Q1 EPS by 1c
- athenahealth, Inc. (ATHN) Misses Q1 EPS by 5c
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
You May Also Be Interested In
- UPDATE: Gilead (GILD) Receives Orphan Status for Chronic Lymphocytic Leukemia Treatment
- Microsoft's (MSFT) Bing: This Time, It's Getting Personal. No, Really
- Tesla (TSLA) Pressured on...Months-Old Article?
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!